QQQ   419.69 (+1.22%)
AAPL   166.29 (+0.78%)
MSFT   401.50 (+0.60%)
META   484.90 (+0.80%)
GOOGL   156.84 (+1.78%)
AMZN   177.49 (+1.64%)
TSLA   141.51 (-3.77%)
NVDA   794.10 (+4.21%)
AMD   148.65 (+1.37%)
NIO   4.00 (+5.26%)
BABA   70.60 (+2.22%)
T   16.27 (-1.45%)
F   12.82 (+5.60%)
MU   109.49 (+2.55%)
GE   150.84 (+1.88%)
CGC   7.89 (-0.50%)
DIS   112.78 (+0.15%)
AMC   3.35 (+6.01%)
PFE   26.40 (+1.54%)
PYPL   63.20 (+1.43%)
XOM   121.26 (+1.15%)
QQQ   419.69 (+1.22%)
AAPL   166.29 (+0.78%)
MSFT   401.50 (+0.60%)
META   484.90 (+0.80%)
GOOGL   156.84 (+1.78%)
AMZN   177.49 (+1.64%)
TSLA   141.51 (-3.77%)
NVDA   794.10 (+4.21%)
AMD   148.65 (+1.37%)
NIO   4.00 (+5.26%)
BABA   70.60 (+2.22%)
T   16.27 (-1.45%)
F   12.82 (+5.60%)
MU   109.49 (+2.55%)
GE   150.84 (+1.88%)
CGC   7.89 (-0.50%)
DIS   112.78 (+0.15%)
AMC   3.35 (+6.01%)
PFE   26.40 (+1.54%)
PYPL   63.20 (+1.43%)
XOM   121.26 (+1.15%)
QQQ   419.69 (+1.22%)
AAPL   166.29 (+0.78%)
MSFT   401.50 (+0.60%)
META   484.90 (+0.80%)
GOOGL   156.84 (+1.78%)
AMZN   177.49 (+1.64%)
TSLA   141.51 (-3.77%)
NVDA   794.10 (+4.21%)
AMD   148.65 (+1.37%)
NIO   4.00 (+5.26%)
BABA   70.60 (+2.22%)
T   16.27 (-1.45%)
F   12.82 (+5.60%)
MU   109.49 (+2.55%)
GE   150.84 (+1.88%)
CGC   7.89 (-0.50%)
DIS   112.78 (+0.15%)
AMC   3.35 (+6.01%)
PFE   26.40 (+1.54%)
PYPL   63.20 (+1.43%)
XOM   121.26 (+1.15%)
QQQ   419.69 (+1.22%)
AAPL   166.29 (+0.78%)
MSFT   401.50 (+0.60%)
META   484.90 (+0.80%)
GOOGL   156.84 (+1.78%)
AMZN   177.49 (+1.64%)
TSLA   141.51 (-3.77%)
NVDA   794.10 (+4.21%)
AMD   148.65 (+1.37%)
NIO   4.00 (+5.26%)
BABA   70.60 (+2.22%)
T   16.27 (-1.45%)
F   12.82 (+5.60%)
MU   109.49 (+2.55%)
GE   150.84 (+1.88%)
CGC   7.89 (-0.50%)
DIS   112.78 (+0.15%)
AMC   3.35 (+6.01%)
PFE   26.40 (+1.54%)
PYPL   63.20 (+1.43%)
XOM   121.26 (+1.15%)
NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

$1.54
-0.02 (-1.28%)
(As of 02:45 PM ET)
Today's Range
$1.49
$1.60
50-Day Range
$1.50
$2.55
52-Week Range
$1.47
$5.12
Volume
125,727 shs
Average Volume
266,252 shs
Market Capitalization
$74.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cue Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
419.5% Upside
$8.00 Price Target
Short Interest
Bearish
8.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.94) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

274th out of 907 stocks

Pharmaceutical Preparations Industry

118th out of 428 stocks

CUE stock logo

About Cue Biopharma Stock (NASDAQ:CUE)

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE Stock Price History

CUE Stock News Headlines

Forecasting The Future: 4 Analyst Projections For Cue Biopharma
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
What 4 Analyst Ratings Have To Say About Silence Therapeutics
Cue Biopharma Inc Ordinary Shares
Cue Biopharma reports Q3 results
See More Headlines
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
4/22/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+419.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-50,730,000.00
Net Margins
-924.10%
Pretax Margin
-924.10%

Debt

Sales & Book Value

Annual Sales
$5.49 million
Book Value
$0.82 per share

Miscellaneous

Free Float
43,662,000
Market Cap
$74.91 million
Optionable
Optionable
Beta
2.02
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives


CUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings
or view top-rated stocks.

What is Cue Biopharma's stock price target for 2024?

4 brokerages have issued 1-year price objectives for Cue Biopharma's stock. Their CUE share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 419.5% from the stock's current price.
View analysts price targets for CUE
or view top-rated stocks among Wall Street analysts.

How have CUE shares performed in 2024?

Cue Biopharma's stock was trading at $2.64 at the beginning of 2024. Since then, CUE stock has decreased by 41.7% and is now trading at $1.54.
View the best growth stocks for 2024 here
.

When is Cue Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CUE earnings forecast
.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The company earned $0.19 million during the quarter, compared to analysts' expectations of $0.30 million. Cue Biopharma had a negative net margin of 924.10% and a negative trailing twelve-month return on equity of 112.26%.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Wedmont Private Capital (0.08%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends
.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CUE) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners